Concepedia

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)

Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, Lynne I. Wagner, Shankar Srinivasan,

Clinical Lymphoma Myeloma & Leukemia · 2018 · 33 citations · 11 references

DOIFull text

Open access

Concepts

References

11

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

, , +10

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy et al. · Leukemia · 2013 · 1.4K citations · Full text

, , +12

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology · 2004 · 740 citations · Full text

, , +14

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Paul G. Richardson, Hannah Briemberg, Sundar Jagannath et al. · Journal of Clinical Oncology · 2006 · 650 citations · Full text

, , +17

Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance

V. Eleutherakis-Papaiakovou, Aristotelis Bamias, Dimitra Gika et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 228 citations

, , +15